Faeth Therapeutics, a clinical-stage biotechnology company advancing therapies that systematically target tumor metabolism, ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...

Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick Institute and Vividion Therapeutics discovered a compound that blocks the ...

Celcuity Inc. surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer. Read why ...

When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. The study shows that ...

A comprehensive, multi-phase investigation published in Advanced Science suggests that the amino acid tryptophan (Trp) may be a key determinant of therapeutic response to conventional synthetic ...

Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...